N/A N=38 Desaturation Validation of INVSENSOR00039
Healthy
Primary: Oxygen Saturation (SpO2) Accuracy of Sensor — 1.0 percentage of oxygen saturation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Medication Development for Opioid and Alcohol Abuse
Opioid-use Disorder · Alcohol Use Disorder
Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale
N/A N=11 Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain
Spinal Cord Injuries · Neuropathic Pain
Primary: Change in Pain Relief With Visual Analog (VAS) Pain Scale — 3.586; 5.494; 4.041; 5.677 score on a scale
Phase 3 N=1,538 Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Alive (Overall Survival) — 90.0; 91.0 percentage of participants — p=0.22
Phase 4 N=48 Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
Insomnia · Bipolar Disorder
Primary: Change in Subjective Total Sleep Time - Acute — 7.04; 7.03; 7.53; 7.20 hours — p=0.10
Phase 2 N=38 Trial of Roflumilast in Asthma Management (TRIM)
Asthma · Obesity
Primary: Change in Asthma Control Test Score — 2; 2.6 units on a scale
N/A N=140 A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion
Chin Retrusion · Chin Augmentation
Primary: Evaluate Effectiveness of the Treatment Using the Galderma Chin Restrusion Scale — 87; 2 Participants
N/A N=24 Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers
Diabetic Foot Ulcer · Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1c) at 12-week Session — 8.0; 7.0 percentage of HbA1c — p=.26
Phase 2 N=76 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Central Nervous System Embryonal Tumor With Rhabdoid Features · Central Nervous System Embryonal Tumor, Not Otherwise Specified · Central Nervous System Ganglioneuroblastoma
Primary: Maximum Tolerated Dose (MTD) — 90; 85 mg/m^2
N/A N=57 Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome
Fibromyalgia · FMS
Primary: Fibromyalgia Impact Questionnaire, Revised (FIQ-R) Score — 40.8; 45.3; 38.0; 39.4 score on a scale — p=0.28
N/A N=301 Investigating Idiopathic Pulmonary Fibrosis in Greece
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit — 83; 162; 13; 43 Participants
Phase 2 N=40 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
BRCA1 Gene Mutation · BRCA2 Gene Mutation · Ovarian Serous Adenocarcinoma
Primary: Incidence of Dose-limiting Toxicities (DLTs) Defined as the Rate of Drug-related Grade 3-5 Adverse Events Assessed Using the National Cancer Institute Common Terminology…
Phase 3 N=539 Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia · Leukemia
Primary: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia — 31.9; 15.1 months — p=0.0324
N/A N=72 Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy
Rectocele
Primary: Post-operative Posterior Compartment Pain Scores - Posterior Repair — 32; 29; 2; 4 Participants — p=0.32
Phase 2 N=27 Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Transitional Cell Carcinoma
Primary: Overall Response Rate — 3; 6; 9; 7 Participants